Antifungal agents in clinical and preclinical development: overview and analysis

This report presents the first World Health Organization (WHO) analysis of antifungal agents in clinical and preclinical development. It covers systemic antifungal drugs in development worldwide, including label extension and repurposed products, and critically evaluates how well the current pipeline addresses infections caused by WHO fungal priority pathogens. 

The scope of the report is to provide an overview of the current research and development (R&D) landscape and to foster the development of antifungal agents for the most urgent unmet medical needs. The review also highlights some of the financial and technical limitations associated with current R&D of antifungal drugs, including issues related to access and availability particularly in low-resource settings. 

This report is part of the WHO’s efforts to monitor, coordinate and strengthen global R&D efforts to address the ongoing void in antimicrobial drug development. 

All of the data contained in this report can be downloaded from the WHO Global Observatory on Health R&D:

Antifungal pipeline dashboard and data (2024)